Comparison of a high-throughput mass spectrometry method and radioactive filter binding to assay the protein methyltransferase PRMT5

Assay and Drug Development Technologies

Volumn 13, Issue 4, 2015, Pages 235-240

  Maegley, Karen A ^a   Krivacic, Cody ^a   Bingham, Patrick ^a   Liu, Wei ^a   Brooun, Alexei ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 5; PROTEIN METHYLTRANSFERASE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; PRMT5 PROTEIN, HUMAN;

ARTICLE; COMPARATIVE EFFECTIVENESS; COMPETITIVE INHIBITION; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; HISTONE CODE; HISTONE METHYLATION; IC50; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID SCINTILLATION COUNTING; MASS SPECTROMETRY; RADIOACTIVE FILTER BINDING ASSAY; RADIOACTIVITY; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION; SUBSTRATE CONCENTRATION; BINDING SITE; COMPARATIVE STUDY; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; PROCEDURES; RADIOMETRY;

BINDING SITES; ENZYME ASSAYS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MASS SPECTROMETRY; PROTEIN-ARGININE N-METHYLTRANSFERASES; RADIOMETRY;

EID: 84935829957     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.640     Document Type: Article

References (28)

1. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000;403:41-45.
2. Dawson Mark A, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
3. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007;128:683-692.
4. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010; 31:27-36.
5. Wee S, Dhanak D, Li H, et al.: Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 2014;1309:30-36.
6. Richon VM, Johnston D, Sneeringer CJ, et al.: Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 78:199-210.
7. Copeland RA: Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-732.
8. Copeland RA: Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discov Today Ther Strategies 2012;9:e83-e90.
9. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M: Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
10. Knutson SK, Kawano S, Minoshima Y, et al.: Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13:842-854.
11. Wigle TJ, Copeland RA: Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Curr Opin Chem Biol 2013;17:369-378.
12. Daigle SR, Olhava EJ, Therkelsen CA, et al.: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013;122:1017-1025.
13. Hajduk PJ, Huth JR, Fesik SW: Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48:2518-2525.
14. Horiuchi KY, Eason MM, Ferry JJ, et al.: Assay development for histone methyltransferases. Assay Drug Dev Technol 2013;11:227-236.
15. Wu G: Assay development: fundamentals and practices. In: Assay Development: Fundamentals and Practices, p. 188. John Wiley and Sons, Hoboken, New Jersey, 2010.
16. Gao J, Liao R, Yu Y, et al.: Absolute quantification of histone PTM marks by MRM-based LC-MS/MS. Anal Chem 2014;86:9679-9686.
17. Antonysamy S, Bonday Z, Campbell RM, et al.: Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci U S A 2012;109:17960-17965.
18. Williams ST, Walport LJ, Hopkinson RJ, et al.: Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates. Epigenetics 2014;9: 1596-1603.
19. Leveridge M, Buxton R, Argyrou A, et al.: Demonstrating enhanced throughput of RapidFire mass spectrometry through multiplexing using the JmjD2d demethylase as a model system. J Biomol Screen 2014;19:278-286.
20. Britton LMP, Gonzales-Cope M, Zee BM, Garcia BA: Breaking the histone code with quantitative mass spectrometry. Expert Rev Proteomics 2011;8:631-643.
21. Plant M, Dineen T, Cheng A, Long AM, Chen H, Morgenstern KA: Screening for lysine-specific demethylase-1 inhibitors using a label-free high-throughput mass spectrometry assay. Anal Biochem 2011;419:217-227.
22. Hutchinson SE, Leveridge MV, Heathcote ML, et al.: Enabling lead discovery for histone lysine demethylases by high-throughput RapidFire mass spectrometry. J Biomol Screen 2012;17:39-48.
23. Janiszewski J, Schneider R, Kapinos B, et al.: Development of a high-speed, multiplexed sample-delivery instrument for LC-MS/MS bioanalysis. Bioanalysis 2012;4:1039-1056.
24. Gurard-Levin ZA, Scholle MD, Eisenberg AH, Mrksich M: High-throughput screening of small molecule libraries using SAMDI mass spectrometry. ACS Comb Sci 2011;13:347-350.
25. Karkhanis V, Hu Y-J, Baiocchi RA, Imbalzano AN, Sif Sd: Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci 2011;36:633-641.
26. Klepacki J, Brunner N, Schmitz V, Klawitter J, Christians U, Klawitter J: Development and validation of an LC-MS/MS assay for the quantification of the trans-methylation pathway intermediates Sadenosylmethionine and Sadenosylhomocysteine in human plasma. Clin Chim Acta 2013;421:91-97.
27. Struys EA, Jansen EEW, de Meer K, Jakobs C: Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stableisotope dilution tandem mass spectrometry. Clin Chem 2000;46:1650-1656.
28. Chan-Penebre E, Kuplast KG, Majer CR, et al.: A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol 2015; advance online publication.